The Market For DNA-Sequencing-Based Down Syndrome Tests Could Exceed $6 Billion - Don't Screen Us Out

The Market For DNA-Sequencing-Based Down Syndrome Tests Could Exceed $6 Billion

Jan 28, 2014 | Media

On Wednesday night the New England Journal of Medicine published a study showing that a new, DNA-sequencing based blood test provides a dramatic improvement in accuracy at screening for Down syndrome and a second, deadly disorder. That could open up a $6 billion market to the biotechnology companies that are already marketing these tests.

Each year in the U.S. there are 6.6 million pregnancies and 4 million births, according the Centers for Disease Control & Prevention. The list prices of the tests, which are sold by four different companies, range from $700 to $2500. Assuming that pricing settles in the middle of that range and that there are 5 million women who choose to have the test, that would be a $8 billion market.

To read the full article click here.

keep up to date

with the latest campaign developments and find out how you can help create a world where people with Down’s syndrome are equally valued

Follow us

FacebookYoutubeTikTokInstagramTwitter

latest media

Heidi Crowter’s Court of Appeal hearing announcement

Heidi Crowter’s Court of Appeal hearing is scheduled for the 13th July. Keep up to date and support the case here: https://www.crowdjustice.com/case/downrightdiscrimination/ Click on the image below to view the easy read.

Share this page:

Related